Precision Medicine Quarterly

About adminpmls2016

This author has not yet filled in any details.
So far adminpmls2016 has created 203 blog entries.

MolDx Reimbursement Decision Likely to Have Negative Impact on CareDx, Natera Transplant Businesses

2023-03-08T08:25:21-05:00March 8th, 2023|

Palmetto MolDx updated its reimbursement guidance for molecular tests assessing rejection risk in solid organs with more restrictive language concerning appropriate use and testing frequency, a decision that could have negative implications for CareDx and Natera. A Billing Article effective March 31 limits reimbursement to one test per patient encounter, provides new coding to [...]

VieCure, Exact Sciences Partner to Ease Genomic Testing Access, Interpretation

2023-03-08T08:22:20-05:00March 8th, 2023|

Informatics and clinical decision support firm VieCure said Monday that it has entered a strategic collaboration with Exact Sciences aimed at improving access to precision oncology diagnostics for US patients and community oncologists. Under the agreement, Denver-based VieCure will integrate Exact Sciences’ portfolio of diagnostic tests —beginning with the Oncotype DX breast cancer recurrence [...]

Sophia Genetics Q4 Revenues Grow 23 Percent on Strong Data Analysis Sales

2023-03-08T08:20:04-05:00March 8th, 2023|

Sophia Genetics said Tuesday before market opening that its 2022 fourth quarter revenues grew 23 percent to $13.4 million from $10.9 million a year earlier, beating analysts' average estimate of $12.9 million. On a constant currency basis, revenues grew 36 percent, while constant currency revenue growth excluding COVID-19-related revenue was 44 percent. The Swiss [...]

Invitae’s PCM Assay for Minimal Residual Disease Detection Nabs Coverage by Blue Shield of California

2023-03-08T08:18:27-05:00March 8th, 2023|

Invitae said Monday that Blue Shield of California has updated its policy to cover its Personalized Cancer Monitoring (PCM) assay, a tumor tissue-informed, patient-specific technology to detect minimal residual disease in cancer patients. The policy, effective March 1, considers the test medically necessary for patients with stages I-IV cancer after surgical intervention for adjuvant [...]

Caris to Provide Biomarker Discovery, Molecular Testing for Incyte Oncology Drug Development

2023-03-08T08:16:41-05:00March 8th, 2023|

Caris Life Sciences said Tuesday that it has entered a strategic research partnership with Wilmington, Delaware-based Incyte to augment precision medicine approaches for the drugmaker's oncology pipeline. Under the terms of the agreement, Incyte will use Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for two oncology [...]

Personalis, AstraZeneca Extend Collaboration Around Residual Cancer Detection Test

2023-03-08T08:13:14-05:00March 8th, 2023|

Personalis said Tuesday that it is continuing a collaboration with AstraZeneca to explore the cancer sequencing firm's Next Personal molecular residual disease (MRD) test in clinical research and drug development. The two companies are evaluating the sensitivity and specificity of whole-genome-informed circulating tumor DNA testing that supports both residual disease detection and assessment of [...]

Blueprint Medicines Reports Second Quarter 2022 Results

2022-08-10T21:02:03-05:00August 10th, 2022|

Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2022. "We are now one year into the AYVAKIT launch in advanced systemic mastocytosis (SM) and continue to see a significant expansion of our prescriber base as well as strong patient demand, reinforcing [...]

GenomOncology and Congenica announce collaborative development of novel Precision Oncology Solution

2022-08-10T20:54:23-05:00August 10th, 2022|

Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution. Driven by the increasing adoption of cancer genomics and the growing need to individualize therapeutic recommendations, Congenica is developing a [...]

Go to Top